Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Clot removal vs. meds: which works better for mild stroke?

NCT ID NCT06778226

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a procedure to remove a blood clot from the brain (endovascular therapy) works better than medication alone for people with mild stroke symptoms and a visible clot. About 4,800 adults with mild stroke were included. The goal was to see which approach leads to better recovery and fewer complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

4,827 people

The number who actually took part.

Started

Jan 2018

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All acute stroke patients treated at participating sites in North America, South America, Europe, Asia, and Australia.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Acute ischemic stroke in an adult patient (18 years of age or older). 2. Onset (Last Seen Normal) time to treatment time \<24 hours or unknown Last Seen Normal in whom Endovascular Therapy could be considered per local radiographic guidelines. 3. Mild stroke defined as an NIH Stroke Scale ≤ 5 at the time of treatment decision. a. Patients with NIH Stroke Scale=0 can be included in the study if they have relevant abnormalities on neurological exam. 4. An acute intracranial vessel occlusion (Intracranial Internal Carotid Artery terminus (T or L clot), Middle Cerebral Artery (M1, M2, M3/beyond), Anterior Cerebral Artery (A1, A2, A3), V4, Basilar, Posterior Cerebral Artery) defined by non-invasive acute imaging (Computed Tomography, angiography (Computed Tomography Angiography) or Magnetic Resonance angiography (MRA)) that is neurologically relevant to the presenting symptoms and signs. Exclusion Criteria: 1. Stroke symptoms due to another non-ischemic acute neurological condition such as seizure with Post-ictal Todd's paralysis or focal neurological signs due to severe hypo- or hyperglycemia. 2. Hyperdensity on Non-contrast Computed Tomography consistent with intracranial hemorrhage. Any clinical suspicion of any intracranial hemorrhage even in the absence of visible blood on baseline brain imaging. 3. Large acute stroke \>1/3 Middle Cerebral Artery territory or Alberta Stroke Programme Early CT score (ASPECTS\<6 or established frank hypodensity relevant to the presenting acute stroke already visible on baseline CT scan. 4. Findings on acute CT or MRI to suggest that the 5. Patient has a severe or fatal or disabling illness that will impact decision regarding acute reperfusion therapies. 6. Pregnancy. 7. Clinical history, past imaging and clinical judgment suggest that the intracranial occlusion is chronic. 8. Stroke occurred as an inpatient. 9. Inclusion into any randomized control trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boston Medical Center

    Boston, Massachusetts, 02118, United States

  • Brown University

    Providence, Rhode Island, 02912, United States

  • University of Miami

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.